BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22994779)

  • 1. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population.
    Li HY; Ge X; Huang GM; Li KY; Zhao JQ; Yu XM; Bi WS; Wang YL
    Asian Pac J Cancer Prev; 2012; 13(7):3465-9. PubMed ID: 22994779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
    Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
    Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERCC1 and XPD/ERCC2 polymorphisms' predictive value of oxaliplatin-based chemotherapies in advanced colorectal cancer has an ethnic discrepancy: a meta-analysis.
    Lu X; Xiao S; Jin C; van der Straaten T; Li X
    J Clin Lab Anal; 2012 Jan; 26(1):10-5. PubMed ID: 24833529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
    Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
    Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
    Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
    Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of ERCC2 Lys751Gln and GSTP1 Ile105Val gene polymorphisms in colorectal cancer patients: relationships with treatment outcome.
    Le Morvan V; Smith D; Laurand A; Brouste V; Bellott R; Soubeyran I; Mathoulin-Pelissier S; Robert J
    Pharmacogenomics; 2007 Dec; 8(12):1693-703. PubMed ID: 18085999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.
    Shahnam A; Ridha Z; Wiese MD; Kichenadasse G; Sorich MJ
    Pharmacogenomics; 2016 Oct; 17(15):1725-1732. PubMed ID: 27636246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
    Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
    Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.
    Yin M; Yan J; Martinez-Balibrea E; Graziano F; Lenz HJ; Kim HJ; Robert J; Im SA; Wang WS; Etienne-Grimaldi MC; Wei Q
    Clin Cancer Res; 2011 Mar; 17(6):1632-40. PubMed ID: 21278243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
    Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
    Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
    BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients.
    Hao T; Feng W; Zhang J; Sun YJ; Wang G
    Asian Pac J Cancer Prev; 2012; 13(8):3821-4. PubMed ID: 23098477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population.
    Ni M; Zhang WZ; Qiu JR; Liu F; Li M; Zhang YJ; Liu Q; Bai J
    Sci Rep; 2014 Feb; 4():4112. PubMed ID: 24531312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients.
    Jun L; Haiping Z; Beibei Y
    Swiss Med Wkly; 2009 Dec; 139(49-50):724-8. PubMed ID: 20047135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.
    Inada M; Sato M; Morita S; Kitagawa K; Kawada K; Mitsuma A; Sawaki M; Fujita K; Ando Y
    Int J Clin Pharmacol Ther; 2010 Nov; 48(11):729-34. PubMed ID: 20979931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors.
    Yang LM; Li XH; Bao CF
    Asian Pac J Cancer Prev; 2012; 13(11):5883-6. PubMed ID: 23317281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].
    Liu YP; Ling Y; Zhang YP; Liu BR
    Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(4):256-9. PubMed ID: 21418871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
    Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
    Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
    Liang J; Li QF; Yao RY; Lü HY; Jiang J; Sun YY; Song SA; Jiang T
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):515-9. PubMed ID: 21029695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.